UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31

Unicycive Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$3.51+0.15 (+4.46%)

Close on Oct 19, 2026

Market cap: $94.48M
P/E (TTM): –
Dividend yield: –

Unicycive Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	–	–	0.68	0.95	–	–
Research & Development	9.12	20	13	12	6.08	1.02
Selling, General & Admin	–	–	–	0.38	0.25	0.06
General & Administrative	20	12	8.55	6.57	2.90	1.01
Operating Expenses	30	32	21	19	8.98	2.02
Operating Income	-30	-32	-21	-18	-8.98	-2.02
Interest Expense	0.07	0.07	0.08	0.01	0.63	0.24
Interest & Investment Income	1.01	1.26	0.62	–	–	–
Other Non-Operating Income	2.96	-4.61	-9.77	-0.01	-1.04	-0.24
Net Income incl. Noncontrolling Interests	–	–	–	–	-10	-2.26
Net Income	-27	-37	-31	-18	-10	-2.26
Net Income to Common	-27	-38	-31	-18	-10	–
EPS (Basic)(per share)	-1.67	-5.65	-12.80	-12.00	-8.60	-2.70
EPS (Diluted)(per share)	-1.67	-5.65	-12.80	-12.00	-8.60	–
Shares Outstanding (Basic, Weighted)(shares)	16	6.70	2.45	1.51	1.17	0.85
Shares Outstanding (Diluted, Weighted)(shares)	16	6.70	2.45	1.51	1.17	0.85
EBITDA	–	–	–	-18	-8.51	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -141.1%

Financial strength

Current ratio: 3.81
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 236.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.77
Dividend yield: –